08.18.25 -- Improving Intracerebral Hemorrhage Research

Delve into the significance of evolving clinical trial models, their potential to remove barriers to participation, and strategies for sponsors to implement hybrid and decentralized designs.

Treatment options for sickle cell disease (SCD) and newly available gene therapies represent a potential cure. However, the latter are costly and thus remain out of reach for many SCD patients.

Social proof—seeing peers safely participate—reduces fear and builds trust in clinical trials. Sharing real stories and community support normalizes participation and boosts enrollment decisions.

Patient Kindness is a supplemental layer of premium support that offers a more seamless clinical trial experience for patients and caregivers with more complex or nuanced needs.

The shift towards decentralized and hybrid trials underscores the significance of EDC in expanding geographic reach, fostering diversity in participant populations, and reduce participant burden.

With the FDA’s new Diversity Action Plan requirements, sponsors are now expected to set clear goals and strategies for enrolling diverse populations in clinical trials.

Condition-based matching is replacing the inefficient, study-by-study model with a patient-centric approach that matches individuals to all relevant trials based on their unique medical profiles.

CSSi offers unmatched depth and breadth in therapeutic expertise, providing full-spectrum, in-house capabilities, positing the organization as a true end-to-end partner in clinical trials.

Unlock the potential for smoother clinical trial operations by taking the next step to streamline processes and set your research site up for long-term success.

Learn how a bioanalytical testing partner with comprehensive solutions and unwavering commitment to quality can help you bring safe and effective drugs to market with confidence.